Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Advanced BRAF-mutant Cancers Clear all
Terminated Phase 1Phase 2 Interventional Results available

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

NCT03580382
View directory record Official record
Conditions
Melanoma
Interventions
Trametinib daily Until PD, CDX-3379 (ERBB3 antibody)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

NCT06208124
View directory record Official record
Conditions
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
Interventions
IMM-6-415
Drug
Lead sponsor
Immuneering Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Phase 1 Interventional

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

NCT02974725
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Melanoma
Interventions
LXH254, LTT462, Trametinib, Ribociclib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

NCT01362296
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
GSK1120212, docetaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
Scottsdale, Arizona • Orange, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Jul 22, 2026, 10:53 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

NCT02109653
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
LGX818
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

NCT01902173
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Magnetic Resonance Imaging, Trametinib Dimethyl Sulfoxide, Uprosertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

NCT06194877
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Ductal Cancer, Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
Interventions
BGB-3245, Panitumumab
Drug
Lead sponsor
MapKure, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Duarte, California • Durham, North Carolina • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

NCT03864042
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Melanoma
Interventions
losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Jul 22, 2026, 10:53 AM EDT
Active, not recruiting Early Phase 1 Interventional

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

NCT03543969
View directory record Official record
Conditions
Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
Interventions
Encorafenib, Binimetinib, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

NCT01512251
View directory record Official record
Conditions
BRAF Mutant Metastatic Melanoma
Interventions
BKM120 Combined with Vemurafenib (PLX4032)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT05538130
View directory record Official record
Conditions
Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer)
Interventions
PF-07799544, PF-07799933
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
58
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

NCT01616199
View directory record Official record
Conditions
Advanced BRAF-mutant Cancers
Interventions
PX-866, vemurafenib
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Tampa, Florida • New York, New York • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

NCT01320085
View directory record Official record
Conditions
BRAF or NRAS Mutant Metastatic Melanoma
Interventions
MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
10
States / cities
Fayetteville, Arkansas • Tampa, Florida • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

NCT01897116
View directory record Official record
Conditions
Melanoma
Interventions
Hydroxychloroquine (HCQ), Vemurafenib (VEM)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

NCT01245062
View directory record Official record
Conditions
Melanoma
Interventions
GSK1120212, Chemotherapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • Fort Myers, Florida • Athens, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Phase 3 Interventional Results available

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

NCT02967692
View directory record Official record
Conditions
Melanoma
Interventions
Spartalizumab, Placebo, Dabrafenib, Trametinib
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
12
States / cities
Encinitas, California • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

NCT01519427
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
Akt inhibitor MK2206, selumetinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • New Brunswick, New Jersey • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

NCT01689519
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Placebo, Vemurafenib, Cobimetinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Jul 22, 2026, 10:53 AM EDT
Withdrawn Phase 3 Interventional

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

NCT02427893
View directory record Official record
Conditions
Melanoma
Interventions
Cobimetinib, Vemurafenib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Study of ASN007 in Patients With Advanced Solid Tumors

NCT03415126
View directory record Official record
Conditions
Cancer, Malignancy, Neoplasia, Neoplasm, Neoplasm Metastasis, Colon Cancer, Colonic Neoplasms, Colon Cancer Liver Metastasis, Metastatic Cancer, Metastatic Melanoma, Metastatic Colon Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer Metastatic, Pancreatic Cancer, Pancreas Cancer, Pancreas Adenocarcinoma, Pancreas Neoplasm, Metastatic Nonsmall Cell Lung Cancer, Metastatic Pancreatic Cancer
Interventions
ASN007: ascending doses, ASN007 RD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

NCT03843775
View directory record Official record
Conditions
Advanced BRAF Mutant Cancers
Interventions
Binimetinib, Encorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

NCT01777776
View directory record Official record
Conditions
Locally Advanced Metastatic BRAF Mutant Melanoma
Interventions
LEE011, LGX818
Drug
Lead sponsor
Array BioPharma
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Aurora, Colorado • Detroit, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

NCT01227889
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436, Dacarbazine (DTIC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
11
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Jul 22, 2026, 10:53 AM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

NCT03972046
View directory record Official record
Conditions
Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin, Tumor Skin, BRAF Gene Mutation
Interventions
Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor)
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 22, 2026, 10:53 AM EDT